¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

2024³â ´ëÇѽÉÀåÇÐȸ ºÎ¿ï°æÁöȸ Ãá°è¿¬¼ö°­Á : 2024-03-23

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 

2024³â ´ëÇѽÉÀåÇÐȸ ºÎ¿ï°æÁöȸ Ãá°è¿¬¼ö°­Á : 2024-03-23
±³À°ÀÏÀÚ : 2024-03-23
±³À°Àå¼Ò : ºÎ»ê º¤½ºÄÚ Á¦1Àü½ÃÀå 311È£

±³À°ÁÖÁ¦ : 2024³â ´ëÇѽÉÀåÇÐȸ ºÎ¿ï°æÁöȸ Ãá°è¿¬¼ö°­ÁÂ

ÁÖÃÖ±â°ü : ´ëÇѽÉÀåÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ºÎ¿ï°æÁöȸ

´ã´çÀÚ : »ç¹«±¹
¿¬¶ôó : 051-240-5070

À̸ÞÀÏ : sericonf@gmail.com

±³À°Á¾·ù : ³»°ú

Âü¼®¿¹»óÀÎ : 150¸í
Èñ¸ÁÆòÁ¡ : 6Á¡

Áö¿ª : ºÎ»ê±¤¿ª½Ã
±³À°½Ã°£ : 6 ½Ã°£ 40ºÐ

¼¼ºÎ¼ö°­·á : 50,000¿ø  

ºñ°í 1. »çÀüµî·Ï 30,000ÇöÀåµî·Ï 50,000  2. Æò»ýȸ¿øÀº »çÀüµî·Ïºñ ¹«·áÀÔ´Ï´Ù. Æò»ýȸ¿ø °¡ÀÔÀ» ¿øÇϽô ȸ¿øÀº 10¸¸¿ø ÀÔ±ÝÈÄ ÇÐȸ·Î ¿¬¶ôÁֽñ⠹ٶø´Ï´Ù.


±¸ºÐ ¿ùÀÏ °­ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ

±³À°½Ã°£ 03¿ù 23ÀÏ ºÎ»ê º¤½ºÄÚ Á¦1Àü½ÃÀå 311È£ 09:00~09:20 Major imaging trials for coronary intervention in 2023 ÃÖÁ¤Ãµ(ºÎ»ê´ëÇб³º´¿ø)

±³À°½Ã°£ 03¿ù 23ÀÏ ºÎ»ê º¤½ºÄÚ Á¦1Àü½ÃÀå 311È£ 09:20~09:40 How to de-escalate the antiplatelet in patients at high bleeding risk °­¹Î±Ô(ÁøÁÖ°æ»ó´ëº´¿ø)

±³À°½Ã°£ 03¿ù 23ÀÏ ºÎ»ê º¤½ºÄÚ Á¦1Àü½ÃÀå 311È£ 09:40~10:00 Calcification: Final enemy for coronary intervention, How to deal with? ÀåÀç½Ä(ºÎ»ê¹éº´¿ø)

Åä·Ð 03¿ù 23ÀÏ ºÎ»ê º¤½ºÄÚ Á¦1Àü½ÃÀå 311È£ 10:00~10:20 Discussion ÀÌ¿ëȯ,ÇѾçõ,¼ÛÀ±¼®,¹Ú¿ëÈÖ(µ¿·¡ºÀ»ýº´¿ø,â¿øÆÄƼ¸¶º´¿ø,ÇØ¿î´ë¹éº´¿ø,â¿ø°æ»ó´ëº´¿ø)

ÈÞ½Ä 03¿ù 23ÀÏ ºÎ»ê º¤½ºÄÚ Á¦1Àü½ÃÀå 311È£ 10:20~10:30 ½Ä»ç ()

±³À°½Ã°£ 03¿ù 23ÀÏ ºÎ»ê º¤½ºÄÚ Á¦1Àü½ÃÀå 311È£ 10:30~10:50 Evaluaion and treatemnt of resistant hypertension ¼­Á¤¼÷(ºÎ»ê´ë¹éº´¿ø)

±³À°½Ã°£ 03¿ù 23ÀÏ ºÎ»ê º¤½ºÄÚ Á¦1Àü½ÃÀå 311È£ 10:50~11:10 Obesity and GLP-1 antagonist ±è°èȯ(°æ»ó´ëº´¿ø)

±³À°½Ã°£ 03¿ù 23ÀÏ ºÎ»ê º¤½ºÄÚ Á¦1Àü½ÃÀå 311È£ 11:10~11:30 Appraoch and treatment for moderate AS ¹Ú¿ëÇö(¾ç»êºÎ»ê´ëº´¿ø)

Åä·Ð 03¿ù 23ÀÏ ºÎ»ê º¤½ºÄÚ Á¦1Àü½ÃÀå 311È£ 11:30~11:50 Discussion À̼ö¿ë,ÀåÁ¤À±,Á¶À±¼º,À¯Á¤³²(¾ç»êºÎ»ê´ëº´¿ø,â¿ø°æ»ó´ëº´¿ø.ÇØ¿î´ë¹éº´¿ø.ÇØ¿î´ë¹éº´¿ø)

ÈÞ½Ä 03¿ù 23ÀÏ ºÎ»ê º¤½ºÄÚ Á¦1Àü½ÃÀå 311È£ 11:50~12:00 Break ()

±³À°½Ã°£ 03¿ù 23ÀÏ ºÎ»ê º¤½ºÄÚ Á¦1Àü½ÃÀå 311È£ 12:10~12:30 A new stratetgy of lipid lowering therapy in ACS ±è¼öÈ«(ºÎ»êº¸Èƺ´¿ø)

±³À°½Ã°£ 03¿ù 23ÀÏ ºÎ»ê º¤½ºÄÚ Á¦1Àü½ÃÀå 311È£ 12:30~12:50 ARNI for heart failure across the range of ejection fraction ÃÖÁ¤Çö(ºÎ»ê´ëº´¿ø)

Åä·Ð 03¿ù 23ÀÏ ºÎ»ê º¤½ºÄÚ Á¦1Àü½ÃÀå 311È£ 12:50~13:10 Discussion ±è¼º¸¸,±è¼öÇü,ÇãÁ¤È£,±è¹Î¿õ.Ȳ¼®Àç(µ¿ÀÇÀÇ·á¿ø,´ëµ¿º´¿ø,°í½Å´ëº´¿ø.â¿øÇѸ¶À½º´¿ø,ÁøÁÖ°æ»ó´ëº´¿ø)

ÈÞ½Ä 03¿ù 23ÀÏ ºÎ»ê º¤½ºÄÚ Á¦1Àü½ÃÀå 311È£ 13:10~13:30 Break ()

±³À°½Ã°£ 03¿ù 23ÀÏ ºÎ»ê º¤½ºÄÚ Á¦1Àü½ÃÀå 311È£ 13:30~13:50 AF ablation in HFrEF and HFpEF ±è±âÈÆ(ºÎ»ê¹éº´¿ø)

±³À°½Ã°£ 03¿ù 23ÀÏ ºÎ»ê º¤½ºÄÚ Á¦1Àü½ÃÀå 311È£ 13:50~14:10 NOAC: clinial recommendations for Asian population À¯°¡ÀÎ(â¿ø°æ»ó´ëº´¿ø)

±³À°½Ã°£ 03¿ù 23ÀÏ ºÎ»ê º¤½ºÄÚ Á¦1Àü½ÃÀå 311È£ 14:10~14:30 PVC assessment and management °ûÇýºó(»ï¼ºÃ¢¿ø´ëº´¿ø)

Åä·Ð 03¿ù 23ÀÏ ºÎ»ê º¤½ºÄÚ Á¦1Àü½ÃÀå 312È£ 14:30~14:50 Discussion ¹Ú¿µ¾Æ,¹ÚÁ¾¼º,±èÇý¸®,ÀÓ¼ºÀÏ(ºÎ»ê¹éº´¿ø,µ¿¾Æ´ëº´¿ø,ÁøÁÖ°æ»ó´ëº´¿ø.°í½Å´ëº¹À½º´¿ø)

ÈÞ½Ä 03¿ù 23ÀÏ ºÎ»ê º¤½ºÄÚ Á¦1Àü½ÃÀå 313È£ 14:50~15:00 Break ()

±³À°½Ã°£ 03¿ù 23ÀÏ ºÎ»ê º¤½ºÄÚ Á¦1Àü½ÃÀå 314È£ 15:00~15:25 TAVR device selection: Which valve to whom ¿ÀÁØÇõ(ºÎ»ê´ëº´¿ø)

±³À°½Ã°£ 03¿ù 23ÀÏ ºÎ»ê º¤½ºÄÚ Á¦1Àü½ÃÀå 315È£ 15:25~15:50 TAVR for bicuspid AV and AR ¾çÅÂÇö(ºÎ»ê¹éº´¿ø)

±³À°½Ã°£ 03¿ù 23ÀÏ ºÎ»ê º¤½ºÄÚ Á¦1Àü½ÃÀå 316È£ 15:50~16:20 LAA closure: When and how? ±èÁß¼±(½ÅÃ̼¼ºê¶õ½º)

Åä·Ð 03¿ù 23ÀÏ ºÎ»ê º¤½ºÄÚ Á¦1Àü½ÃÀå 317È£ 16:20~16:40 Discussion ¹Ú»ó¿ì,Á¶¿ë¶ô,À̽ÿø,ÁøÇÑ¿µ(¿ï»ê´ëº´¿ø.µ¿¾Æ´ëº´¿ø,ÇѼ­º´¿ø,ºÎ»ê¹éº´¿ø)

 

ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" 2024³â ´ëÇѽÉÀåÇÐȸ ºÎ¿ï°æÁöȸ Ãá°è¿¬¼ö°­Á : 2024-03-23""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û ´ëÇÑâ»óÇÐȸ The Wound Meeting 2024 Seoul - 2ÀÏÂ÷ : 2024-03-23
´ÙÀ½±Û Á¦ 36ȸ ´ëÀü¾È°ú¿öÅ©¼ó - ¸Á¸· Áø´Ü°ú Ä¡·áÀÇ ÀÓ»óÀû Àû¿ë : 2024-03-23
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20805 ¼­¿ï 2024 ´ëÇÑ»ê°ú¸¶ÃëÇÐȸ Á¦27Â÷ Çмú´ëȸ : 2024-06-15 0 3 2024-05-27
20804 ÃæºÏ 204 ÃæûºÏµµÀÇ»çȸ Ãá°è Çмú´ëȸ : 2024-06-15 0 4 2024-05-27
20803 ºÎ»ê 2024³â Á¦7ȸ ´ëÇÑÁßȯÀÚÀçÈ°ÇÐȸ Áý´ãȸ : 2024-06-15 0 2 2024-05-27
20802 ºÎ»ê 2024³â ´ëÇÑÁßȯÀÚÀçÈ°ÇÐȸ ¿öÅ©¼¥-±â´ÉÀû Æò°¡ ¹× ÁßȯÀÚ ÀçÈ°ÀÇ ½ÇÁ¦ (¿Ü»ó ÁßȯÀÚ Æ÷ÇÔ) : 2024-06-15 0 5 2024-05-27
20801 ¼­¿ï KLASS 20Áֳ⠱â³ä 2024 ´ëÇѺ¹°­°æÀ§Àå°ü¿¬±¸È¸ Á¦27ȸ Á¤±âÇмú´ëȸ : 2024-06-15 0 2 2024-05-27
20800 °æ±â 2024³â Á¦ 3ȸ Áß¾Ó´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç °³¿øÀÇ ¿¬¼ö°­Á : 2024-06-15 0 2 2024-05-27
20799 ¼­¿ï (¿Â¶óÀÎ) 2024³âµµ ÀÓ»óÁø·áÁöħ Æò°¡À§¿ø ¾ç¼º±³À° : 2024-06-15 0 1 2024-05-27
20798 ¼­¿ï (¿Â¶óÀÎ) ´ëÇѼҾÆû¼Ò³â°ú ºÐ°úÀü¹®ÀÇ ¿¬¼ö±³À° : 2024-06-15 0 0 2024-05-27
20797 ¼­¿ï ´ëÇÑ°áÇÙ¹×È£Èí±âÇÐȸ COPD School 2024 : 2024-06-15 0 0 2024-05-27
20796 ¼­¿ï »óóÀå·ç¿¬±¸È¸ Áý´ãȸ : 2024-06-15 0 0 2024-05-27
20795 Àü³² 2024³â Àü¶ó³²µµÀÇ»çȸ Àü¹Ý±â Çмú´ëȸ : 2024-06-15 0 2 2024-05-27
20794 ¼­¿ï Ç÷°ü¿µ»ó»ý¸®¿¬±¸È¸ IPOP(Imaging and Physiology on Patients with Cardiovascular Disease) 2024 : 2024-06-15 0 0 2024-05-27
20793 ¼­¿ï ´ëÇÑõ½Ä¾Ë·¹¸£±âÇÐȸ ¾à¹°¾Ë·¹¸£±â ½ÉÆ÷Áö¾ö : 2024-06-15 0 2 2024-05-27
20792 ´ëÀü ´ëÇÑÁ¤Çü¿Ü°úÇÐȸ ´ëÀü, ÃæûÁöȸ - Á¦3Â÷ ¿ù·ÊÁý´ãȸ : 2024-06-15 0 0 2024-05-27
20791 ¼­¿ï Á¦51ȸ ´ëÇÑÀÓ»óÇǺÎÄ¡·á¿¬±¸È¸ ±³À°½ÉÆ÷Áö¾ö : 2024-06-15 0 4 2024-05-27
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷